Bumpy EU Review Ends Well For Selinexor Filing
Karyopharm says its treatment for patients with refractory multiple myeloma could become its first product to be approved in Europe.
Karyopharm says its treatment for patients with refractory multiple myeloma could become its first product to be approved in Europe.